News headlines about Apricus Biosciences (NASDAQ:APRI) have trended somewhat positive on Monday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apricus Biosciences earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.6543863763339 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Apricus Biosciences (APRI) Given Buy Rating at HC Wainwright (americanbankingnews.com)
- Apricus Bio closes stock offering (seekingalpha.com)
- Apricus Biosciences Announces Closing of $3.55 Million Public Offering (finance.yahoo.com)
- Global Erectile Dysfunction Market Opportunities 2018: Bayer AG, K. Chemicals, Cristalia Produtos Quimicos Farmaceuticos, Apricus Biosciences (marketwatch.com)
Shares of APRI stock remained flat at $$0.38 during trading hours on Monday. 1,270,829 shares of the stock traded hands, compared to its average volume of 1,348,741. Apricus Biosciences has a 1 year low of $0.36 and a 1 year high of $3.34. The stock has a market capitalization of $8.44, a price-to-earnings ratio of -0.38 and a beta of 1.35.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Apricus Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 3rd. HC Wainwright lowered shares of Apricus Biosciences from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a report on Friday, February 16th. Finally, ValuEngine upgraded shares of Apricus Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc, a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.